Application of Intraoperative Radiotherapy in Early-Stage Breast Cancer Patients in a Clinical Setting.

IF 1.6 Q4 ONCOLOGY
International Journal of Breast Cancer Pub Date : 2024-06-18 eCollection Date: 2024-01-01 DOI:10.1155/2024/5551907
Ao Wang, Elchanan Quint, Ivan Kukeev, Ravit Agassi, Olga Belochitski, Gay Barski, Julie Vaynshtein
{"title":"Application of Intraoperative Radiotherapy in Early-Stage Breast Cancer Patients in a Clinical Setting.","authors":"Ao Wang, Elchanan Quint, Ivan Kukeev, Ravit Agassi, Olga Belochitski, Gay Barski, Julie Vaynshtein","doi":"10.1155/2024/5551907","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Intraoperative radiation therapy (IORT) has gained popularity in recent years as an alternative to external beam whole breast radiation therapy (WBRT) for early-stage breast cancer. Here, we report 43-month recurrence and survival outcomes in a multiethnic cohort treated with IORT in a clinical context. <b>Method:</b> Two hundred and eleven patients with low-risk features were treated with IORT for early-stage breast cancer from 2014 to 2021. Selection criteria were based on Group Europeen de Curietherapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) guidelines: preferably unifocal intraductal carcinoma (IDC), aged > 50, tumor size ≤ 2.0 cm, and without lymph node involvement. All patients received 20 Gy of radiation dose during the lumpectomy. Information on patient and tumor characteristics was collected. <b>Results:</b> The mean age of this cohort was 67.5 years; 95.2% of patients are Jewish, and the rest are Bedouins (4.7%). Most tumors were intraductal carcinoma (97.2%) and stage 1 (94.8%). The mean follow-up time was 43.4 months. Bedouins had larger tumor sizes (mean 1.21 vs. 1.13 cm) and were younger at diagnosis than Jewish patients (mean 65.4 vs. 67.6 years), although the differences are not significant. The overall recurrence rate was 1.4%. One case of local recurrence (0.5%) and two cases of metastasis (0.9%) were observed during the study period. One patient died from metastasis. <b>Conclusion:</b> Our findings suggest that IORT in selected low-risk patients can achieve an excellent prognosis with low rates of recurrence and metastasis.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2024 ","pages":"5551907"},"PeriodicalIF":1.6000,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11199062/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Breast Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2024/5551907","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Intraoperative radiation therapy (IORT) has gained popularity in recent years as an alternative to external beam whole breast radiation therapy (WBRT) for early-stage breast cancer. Here, we report 43-month recurrence and survival outcomes in a multiethnic cohort treated with IORT in a clinical context. Method: Two hundred and eleven patients with low-risk features were treated with IORT for early-stage breast cancer from 2014 to 2021. Selection criteria were based on Group Europeen de Curietherapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) guidelines: preferably unifocal intraductal carcinoma (IDC), aged > 50, tumor size ≤ 2.0 cm, and without lymph node involvement. All patients received 20 Gy of radiation dose during the lumpectomy. Information on patient and tumor characteristics was collected. Results: The mean age of this cohort was 67.5 years; 95.2% of patients are Jewish, and the rest are Bedouins (4.7%). Most tumors were intraductal carcinoma (97.2%) and stage 1 (94.8%). The mean follow-up time was 43.4 months. Bedouins had larger tumor sizes (mean 1.21 vs. 1.13 cm) and were younger at diagnosis than Jewish patients (mean 65.4 vs. 67.6 years), although the differences are not significant. The overall recurrence rate was 1.4%. One case of local recurrence (0.5%) and two cases of metastasis (0.9%) were observed during the study period. One patient died from metastasis. Conclusion: Our findings suggest that IORT in selected low-risk patients can achieve an excellent prognosis with low rates of recurrence and metastasis.

术中放疗在早期乳腺癌患者中的临床应用。
背景:术中放疗(IORT)作为早期乳腺癌外照射全乳腺放疗(WBRT)的替代疗法,近年来越来越受欢迎。在此,我们报告了一个多种族队列接受 IORT 治疗 43 个月后的复发和生存情况。治疗方法2014年至2021年,211名具有低风险特征的早期乳腺癌患者接受了IORT治疗。选择标准基于欧洲放射治疗和肿瘤学会(GEC-ESTRO)指南:最好是单灶导管内癌(IDC),年龄大于 50 岁,肿瘤大小小于 2.0 厘米,无淋巴结受累。所有患者在肿瘤切除术中都接受了 20 Gy 的放射剂量。收集了患者和肿瘤特征的相关信息。研究结果患者平均年龄为 67.5 岁;95.2% 的患者为犹太人,其余为贝都因人(4.7%)。大多数肿瘤为导管内癌(97.2%)和一期(94.8%)。平均随访时间为 43.4 个月。贝都因人的肿瘤尺寸较大(平均 1.21 厘米对 1.13 厘米),确诊时的年龄也比犹太患者年轻(平均 65.4 岁对 67.6 岁),但差异并不显著。总复发率为 1.4%。研究期间观察到一例局部复发(0.5%)和两例转移(0.9%)。一名患者死于转移。结论:我们的研究结果表明,对选定的低风险患者进行 IORT 治疗可获得良好的预后,且复发率和转移率较低。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.40
自引率
0.00%
发文量
25
审稿时长
19 weeks
期刊介绍: International Journal of Breast Cancer is a peer-reviewed, Open Access journal that provides a forum for scientists, clinicians, and health care professionals working in breast cancer research and management. The journal publishes original research articles, review articles, and clinical studies related to molecular pathology, genomics, genetic predisposition, screening and diagnosis, disease markers, drug sensitivity and resistance, as well as novel therapies, with a specific focus on molecular targeted agents and immune therapies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信